1. Home
  2. PNF vs BEATW Comparison

PNF vs BEATW Comparison

Compare PNF & BEATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PNF
  • BEATW
  • Stock Information
  • Founded
  • PNF 2001
  • BEATW N/A
  • Country
  • PNF United States
  • BEATW United States
  • Employees
  • PNF N/A
  • BEATW 20
  • Industry
  • PNF Finance Companies
  • BEATW Retail: Computer Software & Peripheral Equipment
  • Sector
  • PNF Finance
  • BEATW Technology
  • Exchange
  • PNF Nasdaq
  • BEATW Nasdaq
  • Market Cap
  • PNF N/A
  • BEATW N/A
  • IPO Year
  • PNF N/A
  • BEATW 2021
  • Fundamental
  • Price
  • PNF $7.46
  • BEATW $0.57
  • Analyst Decision
  • PNF
  • BEATW
  • Analyst Count
  • PNF 0
  • BEATW 0
  • Target Price
  • PNF N/A
  • BEATW N/A
  • AVG Volume (30 Days)
  • PNF 29.1K
  • BEATW N/A
  • Earning Date
  • PNF 01-01-0001
  • BEATW N/A
  • Dividend Yield
  • PNF 5.17%
  • BEATW N/A
  • EPS Growth
  • PNF N/A
  • BEATW N/A
  • EPS
  • PNF N/A
  • BEATW N/A
  • Revenue
  • PNF N/A
  • BEATW N/A
  • Revenue This Year
  • PNF N/A
  • BEATW N/A
  • Revenue Next Year
  • PNF N/A
  • BEATW N/A
  • P/E Ratio
  • PNF N/A
  • BEATW N/A
  • Revenue Growth
  • PNF N/A
  • BEATW N/A
  • 52 Week Low
  • PNF $6.37
  • BEATW N/A
  • 52 Week High
  • PNF $9.06
  • BEATW N/A
  • Technical
  • Relative Strength Index (RSI)
  • PNF 41.07
  • BEATW N/A
  • Support Level
  • PNF $7.29
  • BEATW N/A
  • Resistance Level
  • PNF $7.60
  • BEATW N/A
  • Average True Range (ATR)
  • PNF 0.07
  • BEATW 0.00
  • MACD
  • PNF 0.01
  • BEATW 0.00
  • Stochastic Oscillator
  • PNF 53.23
  • BEATW 0.00

About BEATW Heartbeam Inc.

HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

Share on Social Networks: